Business
XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform
XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveT
About this update from Xtalpi Holdings Limited
[{"type":"text","content":"CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases.","length":644,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/XtalPi Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/XtalPi Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":213,"url":"https://media.zenfs.com/en/prnewswire.com/096d1c8437cb84e2a88b2cfea6eea574"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kulhPIgmoSeVNZI4ag87kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM3NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/096d1c8437cb84e2a88b2cfea6eea574","width":400,"height":213}},"href":"https://mma.prnewswire.com/media/2374018/XtalPi_EN_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics.","length":503,"tagName":"p"},{"type":"text","content":"Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. ...